Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HR-positive - 2nd line (L2) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2)

versus exemestane
entinostat plus exemestane
E2112, 2021
  NCT02115282
RCTla/mBC - HR-positive - 2nd line (L2)entinostat plus exemestaneplacebo plus exemestaneWomen and men who had histologically confirmed invasive adenocarcinoma of the breast, metastatic or locally advanced and not amenable to local therapy with curative intent305 / 303low
inconclusive
  • inconclusive 1 % decrease in deaths (OS) (PE)
  • inconclusive 13 % decrease in progression or deaths (PFS) (PE)
ENCORE301, 2013
  NCT00676663
RCTla/mBC - HR-positive - 2nd line (L2)entinostat plus exemestaneplacebo plus exemestanePostmenopausal women with ER-positive BC who were experiencing disease relapse or progression while receiving an NSAI64 / 66NA
suggested
  • suggested 41 % decrease in deaths (OS)
  • inconclusive 27 % decrease in progression or deaths (PFS) (PE)